1
|
Ogier JM, Lockhart PJ, Burt RA. Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice. Hear Res 2020; 386:107870. [PMID: 31864009 DOI: 10.1016/j.heares.2019.107870] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Revised: 11/24/2019] [Accepted: 12/09/2019] [Indexed: 12/20/2022]
Abstract
Many drugs on the World Health Organization's list of critical medicines are ototoxic, destroying sensory hair cells within the ear. These drugs preserve life, but patients can experience side effects including permanent hearing loss and vestibular dysfunction. Aminoglycoside ototoxicity was first recognised 80 years ago. However, no preventative treatments have been developed. In order to develop such treatments, we must identify the factors driving hair cell death. In vivo, studies of cell death are typically conducted using mouse models. However, a robust model of aminoglycoside ototoxicity does not exist. Previous studies testing aminoglycoside delivery via intraperitoneal or subcutaneous injection have produced variable ototoxic effects in the mouse. As a result, surgical drug delivery to the rodent ear is often used to achieve ototoxicity. However, this technique does not accurately model clinical practice. In the clinic, aminoglycosides are administered to humans intravenously (i.v.). However, repeated i.v. delivery has not been reported in the mouse. This study evaluated whether repeated i.v. administration of amikacin or tobramycin would induce hearing loss. Daily i.v. injections over a two-week period were well tolerated and transient low frequency hearing loss was observed in the aminoglycoside treatment groups. However, the hearing changes observed did not mimic the high frequency patterns of hearing loss observed in humans. Our results indicate that the i.v. delivery of tobramycin or amikacin is not an effective technique for inducing ototoxicity in mice. This result is consistent with previously published reports indicating that the mouse cochlea is resistant to systemically delivered aminoglycoside ototoxicity.
Collapse
Affiliation(s)
- Jacqueline M Ogier
- Bruce Lefroy Centre, Murdoch Children's Research Institute, 50 Flemington Road, Parkville, VIC, 3052, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, 3010, Australia.
| | - Paul J Lockhart
- Bruce Lefroy Centre, Murdoch Children's Research Institute, 50 Flemington Road, Parkville, VIC, 3052, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, 3010, Australia
| | - Rachel A Burt
- Bruce Lefroy Centre, Murdoch Children's Research Institute, 50 Flemington Road, Parkville, VIC, 3052, Australia; School of Biosciences, University of Melbourne, Parkville, VIC, 3010, Australia
| |
Collapse
|
2
|
Horvath L, Bächinger D, Honegger T, Bodmer D, Naldi AM. Functional and morphological analysis of different aminoglycoside treatment regimens inducing hearing loss in mice. Exp Ther Med 2019; 18:1123-1130. [PMID: 31316607 PMCID: PMC6601143 DOI: 10.3892/etm.2019.7687] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Accepted: 05/23/2019] [Indexed: 01/05/2023] Open
Abstract
Aminoglycoside ototoxicity is common in clinical practice but reliable protective agents currently do not exist. Aminoglycoside regimens causing ototoxicity in different laboratory animals are under investigation. The assessment method used most commonly to determine auditory effects is the auditory brainstem response (ABR). Distortion product otoacoustic emissions (DPOAE) have been used less frequently. A precise recommendation on the specific method to assess peripheral auditory function before and after aminoglycoside toxicity in mice does not exist. In order to evaluate various mouse models for ototoxic injury caused by various aminoglycoside regimens, there is a need for performing preliminary tests in small cohorts before large experiments. The aim of our study was to investigate different aminoglycoside regimens that cause substantial ototoxic damage in vivo. Aminoglycosides are safe and produce a detectable hearing threshold shift in a small cohort of mice that can be used as a model for preliminary tests. Different ototoxic regimens were assessed by ABR and DPOAE measurements pre- and post-treatment. Further, the sensory cell loss was quantified by counting hair cells in the cochlea. It was revealed that an ototoxic regimen with kanamycin twice daily for 15 consecutive days is safe, well tolerated and produces an early significant hearing threshold shift detected by DPOAE in a small cohort of mice. The study compared ABR and DPOAE in mentioned regimens for the first time and illustrated that DPOAE is well suited for detecting hearing threshold shifts in high frequencies before ABR threshold shifts occur in accordance with predominating outer hair cell damage mainly in the basal turn of the cochlea.
Collapse
Affiliation(s)
- Lukas Horvath
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland.,Department of Biomedicine and The Clinic for Otorhinolaryngology, University Hospital Basel, 4031 Basel, Switzerland
| | - David Bächinger
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Tim Honegger
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Daniel Bodmer
- Department of Biomedicine and The Clinic for Otorhinolaryngology, University Hospital Basel, 4031 Basel, Switzerland
| | - Arianne Monge Naldi
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland
| |
Collapse
|
3
|
Vitamin C alleviates ototoxic effect caused by coadministration of amikacin and furosemide. Pharmacol Rep 2019; 71:351-356. [PMID: 30831441 DOI: 10.1016/j.pharep.2019.01.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2018] [Revised: 12/05/2018] [Accepted: 01/04/2019] [Indexed: 12/21/2022]
Abstract
BACKGROUND Drug-induced ototoxicity is still a main clinical problem in otolaryngology. It is widely known that aminoglycoside antibiotics combined with loop diuretics significantly contribute to permanent ototoxicity. The aim of this study was to find out whether ascorbic acid (vitamin C) is able to reverse or alleviate ototoxicity evoked by systemic (ip) administration of combination of amikacin and furosemide in experimental male albino Swiss mice. METHODS Ototoxic combination of amikacin and furosemide was isobolographically evaluated based on the hearing threshold decreasing doses by 20% and 50% (TDD20 and TDD50), respectively. Linear regression analysis was used to determine the TDD20 and TDD50 values for amikacin, furosemide, vitamin C administered alone and in combination (at the fixed-ratio of 1:1). RESULTS Vitamin C (in a dose of 500 mg/kg, ip) alleviated the impairment in hearing threshold evoked by combined ip administration of amikacin and furosemide (at the fixed-ratio of 1:1) in mice by reducing TDD50 values from 49.82 to 21.56 (p < 0.01). In contrast, vitamin C (500 mg/kg, ip) had no significant effect on TDD20 values for the combination of amikacin and furosemide at the fixed-ratio of 1:1. CONCLUSIONS Vitamin C administered together with ototoxic drug combination of amikacin and furosemide reduced ototoxicity evoked by this two-drug combination in the experimental mice.
Collapse
|
4
|
Abstract
HYPOTHESIS How to induce most efficiently severe sensorineural hearing loss in mice using a single coadministration of an aminoglycoside antibiotic and a loop diuretic? BACKGROUND The coadministration of aminoglycosides and a loop diuretic has been widely used to induce hair cell and spiral ganglion cell loss in guinea pigs. However, the development of new treatment strategies against sensorineural hearing loss, such as tissue engineering techniques, requires the use of mouse models. Previous attempts to induce hearing loss in mice have rendered inconsistent results because of resistance to aminoglycoside-induced ototoxicity. Especially inner hair cells seem to be resistant to aminoglycoside-induced ototoxicity. METHODS In the present study, we aim to optimize hearing loss in mice, using a single high-dose kanamycin (700 and 1,000 mg/kg) injection followed by a furosemide (100 mg/kg) administration. Although previous studies used intraperitoneal furosemide injections 30 minutes after kanamycin administration, we used intravenous furosemide injections administered within 5 minutes after kanamycin treatment. RESULTS Auditory brain stem responses illustrated severe threshold shifts, and histologic analysis showed marked outer hair cell destruction as well as spiral ganglion cell loss. The present protocol results in more severe inner hair cell loss when compared with the results of previous researches. CONCLUSION We conclude that severe sensorineural hearing loss can be induced in mice. Moreover, we found that this mouse model can be augmented via the use of rapid intravenous furosemide administrations to maximize inner hair cell loss.
Collapse
|
5
|
Zadrożniak M, Szymański M, Morshed K, Siwiec H, Klatka J, Łuszczki JJ. Analiza izobolograficzna ototoksycznych interakcji pomiędzy gentamycyną i furosemidem u myszy – doniesienie wstępne. Otolaryngol Pol 2011. [DOI: 10.1016/s0030-6657(11)70652-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Hirose K, Sato E. Comparative analysis of combination kanamycin-furosemide versus kanamycin alone in the mouse cochlea. Hear Res 2010; 272:108-16. [PMID: 21044672 DOI: 10.1016/j.heares.2010.10.011] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2010] [Revised: 10/21/2010] [Accepted: 10/21/2010] [Indexed: 10/18/2022]
Abstract
Combinations of aminoglycosides and loop diuretics have been known to have a synergistic effect in ototoxic injury. Because murine hair cells are relatively resistant to ototoxicity compared to those of other mammals, investigators have turned to combination therapies to create ototoxic lesions in the mouse inner ear. In this paper, we perform a systematic comparison of hearing thresholds, hair cell damage and monocyte migration into the mouse cochlea after kanamycin versus combined kanamycin/furosemide and explore the pathophysiology of enhanced hair cell loss in aminoglycoside ototoxicity in the presence of loop diuretic. Combined kanamycin-furosemide resulted in elevation of threshold not only in the high frequencies, but across all frequencies with more extensive loss of outer hair cells when compared to kanamycin alone. The stria vascularis was severely atrophied and stellate cells in the spiral limbus were missing in kanamycin-furosemide exposed mice while these changes were not observed in mice receiving kanamycin alone. Monocytes and macrophages were recruited in large numbers to the spiral ligament and spiral ganglion in these mice. Combination therapy resulted in a greater number of macrophages in total, and many more macrophages were present further apically when compared to mice given kanamycin alone. Combined kanamycin-furosemide provides an effective method of addressing the relative resistance to ototoxicity that is observed in most mouse strains. As the mouse becomes increasingly more common in studies of hearing loss, and combination therapies gain popularity, recognition of the overall effects of combined aminoglycoside-loop diuretic therapy will be critical to interpretation of the interventions that follow.
Collapse
Affiliation(s)
- Keiko Hirose
- Department of Otolaryngology, Washington University, 660 South Euclid Avenue, Campus Box 8115, St. Louis, MO 63110, United States.
| | | |
Collapse
|
7
|
Time sequence of auditory nerve and spiral ganglion cell degeneration following chronic kanamycin-induced deafness in the guinea pig. Brain Res 2010; 1331:28-38. [DOI: 10.1016/j.brainres.2010.02.058] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2009] [Revised: 02/07/2010] [Accepted: 02/19/2010] [Indexed: 02/06/2023]
|
8
|
Dowdy DW, Needham DM, Mendez-Tellez PA, Herridge MS, Pronovost PJ. Studying outcomes of intensive care unit survivors: the role of the cohort study. Intensive Care Med 2005; 31:914-21. [PMID: 15909168 DOI: 10.1007/s00134-005-2657-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2004] [Accepted: 04/20/2005] [Indexed: 11/30/2022]
Abstract
BACKGROUND As research focuses on long-term patient outcomes and the "real world" effectiveness of intensive care unit (ICU) therapies, the cohort study is increasingly being used in critical care research. METHODS Using examples of prior cohort studies in intensive care, we review the key elements of this research design and evaluate its advantages and limitations for critical care research. Furthermore, through a systematic search of the literature we summarize data from 70 prior published cohort studies of medium- and long-term outcomes in adult critical care medicine. DISCUSSION This research demonstrates that the prospective cohort study is a powerful research design that has not been fully leveraged to assess relationships between exposures and long-term outcomes of ICU survivors. CONCLUSIONS We make recommendations for the design of future cohort studies to maximize the impact of this research in improving the long-term outcomes of critically ill patients.
Collapse
Affiliation(s)
- David W Dowdy
- School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
| | | | | | | | | |
Collapse
|
9
|
Affiliation(s)
- Hassan H Ramadan
- Department of Otolaryngology-Head and Neck Surgery, West Virginia University, Morgantown, West Virginia, USA
| | | |
Collapse
|
10
|
Abstract
Furosemide is an ototoxic diuretic. Furosemide injection is followed by a rapid, but reversible decrease of the endocochlear potential and eighth nerve action potential with a more gradual decrease of the endolymph potassium concentration. In contrast to the reversible effects of furosemide alone on the cochlea, the combination of kanamycin with furosemide resulted in irreversible changes in cochlear function which were associated with elevated levels of kanamycin in the blood and perilymph of the experimental animals. There was a striking similarity between the blood level measured by high pressure liquid chromatography at the time of recovery of auditory function in experimental animals and the ototoxic blood levels proposed by others in clinical literature. These findings help to provide a pharmacologic basis for the clinical observation of furosemide-induced hearing loss.
Collapse
|
11
|
Dolev E, Tamir A, Leventon G. "Is magnesium depletion the reason for ototoxicity caused by aminoglycosides?". Med Hypotheses 1983; 10:353-8. [PMID: 6877116 DOI: 10.1016/0306-9877(83)90002-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Aminoglycoside antibiotic drugs may cause ototoxicity and nephrotoxicity. Our hypothesis postulates that aminoglycosides cause ototoxicity by a mechanism of magnesium depletion in the hair cells of the cochlea. The same mechanism maybe responsible for nephrotoxicity caused by aminoglycosides.
Collapse
|
12
|
Smith CR, Lietman PS. Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother 1983; 23:133-7. [PMID: 6830203 PMCID: PMC184630 DOI: 10.1128/aac.23.1.133] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
We analyzed data from three prospective, controlled, randomized, double-blind clinical trails to determine whether furosemide increases the nephrotoxicity and auditory toxicity of aminoglycosides. All patients who received at least 72 h of treatment and who had no other cause for nephrotoxicity or auditory toxicity were included in the analysis. Nephrotoxicity developed in 10 of 50 (20.0%) patients given furosemide and in 38 of 222 (17.1%) patients not given furosemide (P greater than 0.3). Auditory toxicity developed in 5 of 23 patients (21.7%) given furosemide and in 28 of 119 patients (23.5%) not given furosemide (P greater than 0.3). In each case, the groups receiving and not receiving furosemide did not differ in mean age, initial creatinine, duration of aminoglycoside therapy, mean change in auditory acuity or creatinine, mean number of days to the development of toxicity, the frequency with which gentamicin, tobramycin, amikacin, or cephalothin was administered, or the mean predose and 1-h postdose plasma aminoglycoside levels. We conclude that furosemide use should not be considered a major risk factor for the development of aminoglycoside-induced nephrotoxicity or auditory toxicity.
Collapse
|
13
|
Ohtani I, Ohtsuki K, Aikawa T, Omata T, Ouchi J, Saito T. Individual variation and mechanism of kanamycin ototoxicity in rabbits. Acta Otolaryngol 1982; 94:413-9. [PMID: 7180416 DOI: 10.3109/00016488209128929] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
In order to elucidate the mechanism of individual variation of kanamycin ototoxicity, the possible relationship between the outer hair cell damage induced by kanamycin and the levels of kanamycin in serum or perilymph and of renal damage was investigated in rabbits. No relationship was found between the extent of the outer hair cell damage and the level of kanamycin in the serum or the renal damage. The extent of the outer hair cell damage was closely correlated to the levels of kanamycin in the perilymph. These findings suggest that the individual variations in the outer hair cell damage induced by kanamycin are more closely correlated to the individual differences in the transferability of kanamycin into inner ear than to those in the vulnerability of the outer hair cells or kidneys.
Collapse
|
14
|
Bruun JN, Eng J, Arnesen AR. Tobramycin therapy of serious infections. Pharmacological aspects and side effects. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1981; 13:59-64. [PMID: 7244560 DOI: 10.1080/00365548.1981.11690368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Plasma concentrations and side effects were followed in 52 adults treated with tobramycin for 4-39 days (mean 12.2 days). In order to obtain 1-h peak levels above the recommended 4 microgram/ml in patients with normal renal function, loading doses of 160 mg followed by 100-120 mg every 8 h were usually necessary. Both the leading dose and the mean daily dose of 304 mg were higher than usually recommended. Great individual variations in doses required were found and nomograms were of little value. Reduced maintenance doses were given to patients with impaired renal function. Adequate treatment required plasma level determinations 2-3 times a week. The high dose of tobramycin regimen used in this study implied that 30% of the trough levels exceeded 2 microgram/ml. The frequency of clinically significant side effects were, however, low and the treatment was only interrupted once because of a decrease in renal function. Temporary reduction in renal function probably related to tobramycin was found in 6 patients, and 5 patients got temporary disturbances of vestibular function. One patient experienced a temporary hearing loss and 2 patients a permanent hearing loss, which might have been caused by simultaneous treatment with furosemide and tobramycin.
Collapse
|
15
|
|